Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

The pharmaceutical industry is undergoing a significant transformation - shifting away from the development of blockbuster drugs to a more value-driven approach based, increasingly, on specialty medicines for niche markets and patient outcomes. For the commercial operations landscape, specialty medicines come with their own specific challenges across data integration and data coverage. Further, ...

Incentive Compensation (IC) is one the key drivers of sales force effectiveness. To properly administer a sales incentive program it is important to recognize that IC is a dynamic process that must regularly flex and adjust to marketplace and corporate challenges. As commercial operations teams adjust their plans to account for these conditions, they must also strike a balance to ensure their ...

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines that use new scientific drug delivery systems, e.g., large molecules as opposed to traditional small molecule drugs, catering to smaller patient populations. While this shift solves some problems pharma has been facing, ...

The question this white paper addresses is straightforward – will COVID-19 call for restructuring the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE model has been a go-to metric for sales response modeling, sales force optimization, and sales operations analyses for 20+ years. However, with the implications of COVID-19 on the global healthcare ...

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white paper addresses is what could this policy, if enacted, have on the structure of US and global drug pricing and associated market effects? Specific projected effects are highlighted for both the US and global pharma ...

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry. This comes at a time when industry executives are already facing a myriad of difficult challenges. CEO quotes focus on pricing and innovation & intellectual property (IP) issues, these being the life-blood of any pharma ...

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his verbal comments during speeches, interviews, and tweets. One industry in particular has received special attention – US pharma. President Trump’s comments about the high price of drugs, allowing direct federal government ...

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means ...

The question this commentary asks is simply this - has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceutical companies to the point that they now may well stifle the very innovative environment needed by companies to meet the scientific demands and expectations of society? The answer to this question leads to understanding how ...